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Abstract
Introduction: The TAM (tyro 3, axl, mer) kinases are key regulators of innate immunity and are important in the
phagocytosis of apoptotic cells. Gas6 and protein S are ligands for these TAM kinases and bind to phosphatidyl
serine residues exposed during apoptosis. In animal models, absence of TAM kinases is associated with lupus-like
disease. To test whether human systemic lupus erythematosus (SLE) patients might have deficient levels of TAM
ligands, we measured Gas 6 and protein S levels in SLE.
Methods: 107 SLE patients were recruited. Of these, 45 SLE patients were matched age, gender and ethnicity with
normal controls (NC). Gas6 and free protein S were measured with sandwich enzyme linked immunosorbent assays
(ELISAs).
Results: Overall, the plasma concentrations of Gas6 and free protein S were not different between 45 SLE patients
and 45 NC. In SLE patients, the levels of free protein S were positively correlated with age (r = 0.2405, P = 0.0126),
however those of Gas6 were not. There was no correlation between the concentrations of Gas6 and free protein S
in individuals. Levels of free protein S were significantly lower in SLE patients with a history of serositis, neurologic
disorder, hematologic disorder and immunologic disorder. Gas6 levels were elevated in patients with a history of
neurologic disorder. The SLE patients with anti-Sm or anti-cardiolipin IgG showed lower free protein S levels.
Circulating free protein S was positively correlated with complement component 3 (C3) (r = 0.3858, P < 0.0001)
and complement component 4 (C4) (r = 0.4275, P < 0.0001). In the patients with active BILAG hematologic
involvement, the levels of free protein S were lower and those of Gas6 were higher.
Conclusions: In SLE, free protein S was decreased in patients with certain types of clinical history and disease
activity. Levels of free protein S were strongly correlated with C3 and C4 levels. Gas6 levels in SLE patients differed
little from levels in NC, but they were elevated in the small numbers of patients with a history of neurological
disease. The correlation of decreased protein S levels with lupus disease activity is consistent with a role for the
TAM receptors in scavenging apoptotic cells and controlling inflammation. Protein S appears more important
functionally in SLE patients than Gas6 in this regard.
Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease with diverse presentations. Its patho-
genesis remains elusive; however, multifactorial
interactions among genetic and environmental factors
may be involved [1,2]. SLE is characterized by dysregula-
tion of the immune system that involves hyperactivity of
T cells and B cells, production of pathogenic autoanti-
bodies, and the formation of immune complexes, which
can lead to multiorgan damage.
Certain nuclear and cytoplasmic autoantigens become
clustered in the surface blebs of apoptotic cells [3].
Under normal circumstances, apoptotic cells are
engulfed by macrophages in the early phase of cell
death without inducing inflammation or the immune
response. In SLE, however, the clearance of apoptotic
cells by macrophages is impaired, which may allow
apoptotic cells to serve as immunogens for the
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production of autoantibodies [4].
The reasons for the defective clearance of apoptotic
cells in SLE are not clear. The past decade has provided
s i g n i f i c a n te v i d e n c et h a tc o m p l e m e n td e f i c i e n c i e s ,
immunoglobulin (Ig) M deficiency, pentraxin deficiency
and defects in macrophage handling may each contri-
bute to defective clearance of apoptotic bodies [5-7].
Macrophages recognize apoptotic cells through an array
of surface receptors. Among them, the tyro 3, axl, mer
(TAM) kinases, especially the c-mer receptor tyrosine
kinase, play an especially important role in the clearance
of apoptotic cells [8,9]. Mice lacking c-mer have
impaired clearance of apoptotic cells and develop pro-
gressive lupus-like autoimmunity [10]. The two ligands
that bind to and activate c-mer are growth arrest-speci-
fic 6 (Gas6) and protein S, which in turn bind to phos-
phatidylserine residues exposed early in apoptosis on
the surface of the apoptotic cell [11-14].
Gas6, a 75 kDa multimodular vitamin K-dependent
protein that has 46 to 48% amino acid identity to pro-
tein S, was discovered in the early 1990 s [15]. It con-
tains an N-terminal g-carboxyglutamic acid (Gla)
domain, interacting with phosphatidylserine containing
membranes, followed by four epidermal growth factor-
like domains and a large C-terminal region homologous
to the sex hormone binding globulin, can ligate TAM
receptor tyrosine kinases [16]. Gas6 is expressed in
many tissues, including capillary endothelial cells, vascu-
lar smooth muscle cells, and bone marrow cells. Unlike
protein S, Gas6 is not expressed in the liver, and its
concentration in plasma is 1,000-fold lower than that of
protein S [17].
Protein S has a critical function in regulating coagula-
tion by serving as a cofactor for activated protein C-
dependent proteolytic inactivation of factor Va and fac-
tor-VIIIa. Protein S circulates as approximately 40% free
protein S and 60% as a complex with C4-binding pro-
tein; only free protein S is active as a cofactor for acti-
vated protein C and a ligand for the TAM receptor
kinases. In the absence of free protein S, there is
increased risk of thromboembolism [18].
It is reasonable to hypothesize that Gas6 and protein S
might have important roles in the pathogenesis of SLE.
Recently, plasma Gas6 was reported to be elevated in
patients with severe sepsis, septic shock, and severe acute
pancreatitis [19-21]. However, there are no reports about
Gas6 levels in SLE. Low levels of protein S are reported
in SLE, and could be contributing to the thrombotic pro-
pensity in certain SLE patients [22-24]. We have there-
fore compared Gas6 and free protein S concentrations in
patients with SLE, examining their possible use as bio-
markers of clinical phenotype and/or disease activity.
Materials and methods
Subjects
Samples from 107 SLE patients, participating in the Okla-
homa Cohort for Rheumatic Disease, were studied. All
patients satisfied at least four of the 1982 revised Ameri-
can College of Rheumatology (ACR) criteria for SLE [25].
Forty-five of these SLE patients were matched by age,
gender and ethnicity to healthy normal controls (NC)
(Table 1). Heparinized plasma samples were collected
and stored at -70°C immediately after collection. Infor-
mation on medical history, ACR criteria for SLE, and
current disease activity was registered into a database,
which included no personal identifiers. Laboratory data
included blood cell counts, routine chemistry, urinalysis,
complement levels, anti-dsDNA, anti-Sm, anti-RNP,
anticardiolipin (ACA) IgG and IgM, lupus anticoagulant
(LAC), anti-b2 glycoprotein I, anti-Ro, anti-La, and anti-
protein S antibody. C3 and C4 were measured in the
Oklahoma Medical Research Foundation clinical labora-
tory by standard nephelometric techniques. Disease activ-
ity was scored using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) and the British Isles
Lupus Assessment Group (BILAG) Instrument [26,27].
Prior to participation, all subjects gave informed con-
sent to donate their blood samples and de-identified
clinical information for research, and the study was
approved by the Institutional Review Boards of Okla-
homa Medical Research Foundation and of Temple
University.
Measurement of plasma Gas6 concentrations
Gas6 was measured with a sandwich ELISA modified
from a previously developed and validated protocol [28].
Briefly, 96-well plates were coated overnight with anti-
Gas6 capture antibody (goat polyclonal affinity purified
IgG, R&D Systems, Minneapolis, MI, USA). The antigen
was detected by a secondary biotin-conjugated antibody
(Biotinylated anti-human Gas6 antibody, R&D Systems,
Minneapolis, MI, USA), and a streptavidin-peroxidase
conjugate (R&D Systems, Minneapolis, MI, USA) and
TMB (3,3’,5,5’-tetramethylbenzidine, R&D Systems, Min-
neapolis, MI, USA). The reaction was stopped with 2N
sulphuric acid and absorbance detected at 450 nm. The
absorbance at 450 nm was read with a reference wave-
l e n g t hs e ta t5 7 0n mu s i n gaV e r s a m a xm i c r o p l a t e
reader (Molecular Devices, Sunnyvale, CA, USA). The
optical density (OD) for each point was determined
from the average of duplicate samples. Gas6 concentra-
tions were determined using Softmax software (Molecu-
lar Devices, Sunnyvale, CA, USA) by applying a four-
parameter logistic regression to the calibration curve
prepared from duplicate serial dilutions of purified Gas6
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were 4.52% and 11.8%, respectively.
Measurement of plasma free protein S concentrations
Free protein S levels were quantified using the free pro-
tein S ELISA kit (Diagnostica Stago, Parsippanny, NJ,
USA) according to the manufacturer’s instructions. The
ELISA utilizes two monoclonal antibodies, each specific
for free protein S epitopes [29]. Briefly, heparinized
plasma samples were diluted 1:20 in 1% BSA and dupli-
cate 200 μl samples applied to the precoated 96-well
plate. Serial dilutions of purified protein S (Hematologic
Technologies Inc., Essex Junction, VT, USA) starting at
20 μg/ml were used to construct a standard curve.
These were further diluted 1:20 (in 1% BSA) before
being applied to the plate in duplicate. Four blank wells
received 200 μl 1% BSA. The horseradish peroxidase
(HRP)-conjugated secondary antibody (50 μl/well) was
added immediately. The plate was developed with 200
μl/well of TMB substrate for five minutes as described
for the Gas6 ELISA. The intra-assay and inter-assay CVs
were 6.1% and 13.5%, respectively.
Statistical analysis
The data were expressed as mean ± standard deviation
(SD). An unpaired Student’s t-test was used for statisti-
cal comparison of plasma Gas6 and protein S levels
between matched 45 SLE patients and 45 NC and of
those according to the clinical manifestations in total
107 patients with SLE. When the data did not show
Gaussian distribution, the Mann-Whitney U-test was
used. To detect correlation between continuous data,
the Pearson correlation coefficient was applied. Prizm
software (GraphPad Software, La Jolla, CA, USA) was
employed for all analyses. For all tests, a P value of less
than 0.05 was regarded as significant.
Results
Gas6 and free protein S concentration in SLE and NC
The plasma concentrations of Gas6 were almost identi-
cal between 45 SLE patients and age, gender and ethni-
city matched 45 NC (15.55 ± 4.39 vs. 15.89 ± 6.88 ng/
mL, respectively; Figure 1a). Also, there was no differ-
ence in the level of free protein S between them (6.44 ±
1.75 vs. 6.91 ± 1.74 μg/mL, respectively; Figure 1b). In
examining the levels of free protein S in all 107 SLE
patients, free protein S was positively correlated with
age (r = 0.2405, P = 0.0126), but Gas6 levels did not
increase with age (Figure 2). The concentrations of Gas6
and free protein S were slightly higher in females than
in males, but the difference was not significant.
As Gas6 and protein S are closely related, and both
can function as intermediaries for TAM receptor kinase
binding to apoptotic cells, we evaluated whether their
levels would be related to each other; however, there
was no correlation between the concentrations of Gas6
Table 1 Characteristics of patients
Lupus matched
(n = 45)
Normal control
(n = 45)
Lupus unmatched
(n = 62)
Age (years) 40.47 ± 15.5 41.38 ± 15.9 37.27 ± 13.02
Sex (F:M) 34:11 34:11 51:11
Ethnicity
Caucasian 41 41 54
African 2 2 2
Asian 1 1 3
American Indian 1 1 3
ACR total 5.51 ± 1.69 5.53 ± 1.72
Anti-dsDNA Ab (%) 33.3 22.6
Anti-Sm Ab (%) 28.9 12.5
Anti-Ro (SSA) Ab (%) 42.2 35.5
Anti-La (SSB) Ab (%) 8.9 22.6
Anticardiolipin Ab (%) 48.8 35.7
Lupus anticoagulant (%) 15.6 11.7
Anti-B2 glycoprotein Ab (%) 11.1 14.5
APS (%) 37.8 14.8
Decreased C3 (%) 8.9 4.8
Decreased C4 (%) 42.2 30.7
SLEDAI 6.02 ± 4.3 4.75 ± 4.08
BILAG 6.93 ± 5.34 5.59 ± 3.73
Ab, antibody; ACR total, the number of American College of Rheumatology 1982 revised criteria for classification of systemic lupus erythematosus; APS,
antiphospholipid syndrome; BILAG, British Isles Lupus Assessment Group; F, female; M, male; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
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shown).
Clinical characteristics and Gas6 and free protein S
in SLE patients
The concentrations of free protein S were significantly
lower in SLE patients with a history of serositis, neuro-
logic disorder, hematologic disorder, and immunologic
disorder (defined by meeting 1982 revised ACR criteria
than in those patients without these SLE features (Figure
3). In the patients with antiphospholipid syndrome
(APS), free protein S levels were not different from
patients without a history of APS. Also, free protein S in
patients known to have a history of pathologic thrombo-
sis (with or without meeting autoantibody requirements
for APS) did not differ from those without thrombotic
history. There was no difference in the levels of Gas6 in
any subset of patients excepting neurologic disorder.
Although the number of patients with a history of neu-
rologic disorder was only five, they had elevated Gas6
levels compared with patients without a history of neu-
rologic disorder (Figure 3e).
Free protein S was slightly lower in the patients with
anti-dsDNA than those without, but the difference was
not significant. The SLE patients with anti-Sm showed
lower free protein S levels than those without (Figure
4a).
There are conflicting reports about free protein S
levels in the patients with antiphospholipid antibody
[22,23,30-33]. Our study found concentrations of free
protein S to be lower in the patients with ACA (Figure
4b). However, there were no differences in the levels of
free protein S between patients with and without LAC
and anti-b2 glycoprotein I, respectively.
Among five SLE patients with anti-protein S antibo-
dies, four had a history of thrombosis and three patients
were positive for ACA; however, their acute levels of
free protein S were not different from the patients with-
out anti-protein S antibodies (data not shown).
Protein S levels correlate with C3 and C4 in SLE patients
T h ec o n c e n t r a t i o n so ff r e ep r o t e i nSw e r el o w e ri n
patients with decreased C3 or C4, markers commonly
used in assessing disease activity. It was striking that
Figure 1 Plasma levels of (a) Gas6 and (b) free protein S in
age, gender and ethnicity matched SLE and NC. NC, normal
controls; SLE, systemic lupus erythematosus.
Figure 2 Plasma concentrations of (a) Gas6 and (b) free protein
S in SLE patients according to age. SLE, systemic lupus
erythematosus.
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(r = 0.3858, P < 0.0001; Figure 5a) and C4 (r = 0.4275,
P < 0.0001; Figure 5b).
Disease activity and Gas6 and protein S in SLE patients
We assessed overall disease activity with SLEDAI and
BILAG composite scores, but did not find any correla-
tion in a cross-sectional population comparison with
levels of Gas6 or free protein S.
In the subset of patients with active BILAG hematolo-
gic involvement, whose BILAG score is not zero, the
levels of Gas6 were higher (23.05 ± 24.88 vs 16.99 ±
6.93 ng/mL, P = 0.008; Figure 5c) and those of free pro-
tein S were lower (6.14 ± 0.46 vs 7.16 ± 2.37 μg/mL,
P = 0.036; Figure 5d) compared with patients without
BILAG hematologic involvement. In addition, the
patients with a BILAG score greater than or equal to
three showed further increased concentration of Gas6
(29.93 ± 24.88 ng/ml) and those of free protein S (5.57
± 0.46 μg/mL).
Discussion
Abnormal clearance of apoptotic cells may be important
in the development of autoantibodies in SLE. As the
TAM kinases may be important in the disposition of
apoptotic cells, we evaluated plasma concentrations of
their ligands Gas6 and free protein S. Although the
levels of Gas6 and free protein S were not different
Figure 3 Gas6 and free protein S levels according to the clinical manifestations in SLE. Free protein S in patients with (a) serositis, (b)
neurologic disorder, (c) hematologic disorder, (d) immunologic disorder. Gas6 plasma levels in patients with (e) neurologic disorder. SLE,
systemic lupus erythematosus.
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controls, free protein S was decreased in subsets of SLE
patients with a history of serositis, neurologic, hematolo-
gic, and immunologic disorder. It was especially note-
worthy that the concentrations of free protein S were
correlated with C3 and C4. Protein S was decreased in
SLE patients with active hematologic disease as defined
by the BILAG index. In contrast to the findings for pro-
tein S, reduced levels of Gas6 were not associated with
more active disease, with the possible exception of neu-
rologic disorder, although this analysis was limited by a
small number of patients. Surprisingly, active hematolo-
gic disease as defined by BILAG revealed an unexpected
association with elevated, not reduced Gas6 levels.
Protein S is a vitamin K-dependent plasma anticoagu-
lant protein and its deficiency leads to hypercoagulabil-
ity syndromes with increased risk for venous
thrombosis. However, there have been limited reports
about functional effects of protein S independent of its
anticoagulant function. After identification of TAM
k i n a s e sa sr e c e p t o r sf o rp r o t e i nS ,t h i sp r o t e i nw a s
shown to be required for the efficient uptake of
apoptotic cells by macrophages in vitro [34], suggesting
an important role in immune clearance. Protein S may
play a particularly significant role in the removal of
apoptotic cells because of its high plasma concentration,
despite its apparent lower affinity for the receptor than
Gas6. In the study of c-mer-mediated phagocytosis of
apoptotic cells, protein S stimulated phagocytosis as well
as or better than Gas6 [35,36]. Therefore, it is possible
that insufficient levels of protein S may lead to ineffi-
cient clearance of apoptotic cells, resulting in exposure
of cellular contents to immune cells and promoting an
autoimmune response.
Several reports have suggested that the levels of free
protein S may be lower in patients with SLE [22,23,32].
In the present study, there was no significant difference
overall in circulating free protein S between patients
with SLE and matched healthy controls. However, the
concentrations of free protein S did appear to be
decreased in subsets of those patients with a history of
certain clinical manifestations, and low protein S corre-
lated with acute evidence of hematologic disease activity
and complement consumption. These findings support
the possibility of a novel functional link between the
coagulation system and distinct inflammatory responses
in SLE. It is well known that there is increased cardio-
vascular mortality and morbidity among SLE patients,
which is not fully explained by traditional risk factors
[37,38]. Our results raise the possibility that, in a defin-
able subset of patients with SLE, disease activity may
lead to a decrease in the level of free protein S, which
then may increase thrombogenicity. It should be consid-
ered that the protein that regulates levels of free protein
S is the C4b-binding protein, which is a critical comple-
ment regulator as well [39]. The failure in our series to
find decreased levels of protein S in patients with pre-
vious thrombosis could reflect the very small number of
patients in that category, along with the multiple risk
factors that are probably involved in the pathologic
hypercoagulability of SLE. Additionally, this was a cross-
sectional analysis, whereas at least one report has sug-
gested that decreased free protein S may be more likely
to be observed closer in time to a thrombotic event in
patients with SLE [40]. Although decreased protein S
levels may be secondary to SLE activity, we favor the
hypothesis that a decrease in protein S may actually
contribute to SLE pathogenesis, as discussed above and
suggested by Rothlin and colleagues [41].
Previous reports have observed an association between
reduced levels of free protein S and antiphospholipid
antibody in SLE [23,30]. It has been suggested that
acquired protein S deficiency could contribute to
increased risk of thrombosis in patients with antipho-
spholipid antibody. However, other investigations have
not confirmed an association [22,31-33]. These reports
Figure 4 Levels of free protein S according to the presence of
autoantibodies in SLE. Free protein S in patients with (a) anti-Sm
and (b) anticardiolipin (ACA). SLE, systemic lupus erythematosus.
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SLE patients (30 to 50 patients). In the present study
assessing 107 SLE patients, free protein S levels were
significantly lower only in those patients with ACA, but
not in those with LAC and anti-b2 glycoprotein I. Auto-
antibodies directed against protein S have been asso-
ciated with thrombosis in patients with APS and SLE
[32,42-44]. However, the presence of anti-protein S anti-
bodies in patients have not been found to reduce the
concentrations of free protein S [32,42]. Our findings
were consistent with these results although the preva-
lence of anti-protein S was lower in our patients (5%)
than previous reports (26 to 31%).
Gas6 is a cell survival, proliferation and chemotactic fac-
tor and also a recognition bridge between phagocytes and
apoptotic cells. Gas6 is present at a low concentration in
plasma; however, it can be released by endothelial cells
and leukocytes during serum starvation or under inflam-
matory conditions [19,21,45-47]. The receptors that bind
Gas6 (Tyro3, Axl, and c-mer) have an immunoregulatory
role, modulating macrophage activation following an
initial immune stimulus [9,48]. Gas6 may thus be sup-
posed to participate in inflammation by interfering with
macrophage-lymphocyte crosstalk. Furthermore, Gas6
might be involved in other chronic systemic autoimmune
diseases, such as rheumatoid arthritis and chronic inflam-
matory demyelinating polyneuropathy [49,50]. It has been
suggested that Gas6 is involved in macrophage activation
in chronic autoimmunity as an autocrine or paracrine reg-
ulatory molecule for monocytes [51].
In the present study, plasma Gas6 levels in patients
with SLE were the same as in matched HC and levels
were unrelated to age and gender. The concentration of
Gas6 was increased in the patients with a history of
neurologic disorder and acute activity in the BILAG
hematology system. The latter results may reflect the
inducible nature of Gas6. Basal levels of Gas6 were low,
yet it is known to be upregulated in certain states of
intense inflammation such as septic shock and severe
acute pancreatitis [19-21]. A recent report finding that
almost all Gas6 present in healthy subjects is bound by
soluble Axl may explain why there is actually little free
Gas6 present in either normal or SLE serum, although
the extent to which our ELISA can detect axl-bound
Gas6 has not been tested [52].
In SLE, free protein S was decreased in patients char-
acterized by a history of serositis, neurologic, hematolo-
gic, and immunologic disorder. Protein S was also
decreased in patients with low C3 and C4 and active
hematologic activity. Thus, free protein S may be useful
as a biomarker of clinical phenotype and disease activity.
Furthermore, the decrease of protein S and increase of
Gas6 in patients with acute activity in the BILAG hema-
tologic system suggests the possibility of a unique link
between inflammation and thrombotic risk that could
be explored mechanistically.
Conclusions
The TAM ligands are important apoptotic debris recep-
tors and regulators of innate immunity. Our study
shows that low levels of one TAM ligand, protein S,
correlate with C3 and C4 levels and with clinical mani-
festations of SLE. In contrast, circulating levels of Gas6,
the other principal TAM ligand, have little apparent
Figure 5 Gas6 and free protein S levels and disease activity. Correlation between free protein S and (a) C3 or (b) C4. (c) Gas 6 and (d) free
protein S levels in patients with BILAG hematology. BILAG, British Isles Lupus Assessment Group.
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These data support the view that ligation of the TAM
ligands through protein S but not Gas6 is important in
clearance of debris and regulation of the innate immune
system in patients with SLE.
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